This study aims to develop the quantitative biomarker to establish the individualized strategy in stroke rehabilitation. Brain-derived neurotrophic factor (BDNF) acts on certain neurons of the central nervous system (CNS) helping to support the survival of existing neurons, and encourage the growth and differentiation of new neurons and synapses. BDNF in CNS can be assessed by analysing serum BDNF. The final objective of this study is to demonstrate a role of biomarker of BDNF in stroke rehabilitation to establish the individualized strategy.
Serum BDNF, proBDNF and MMP-9 in all participants will be measured before and after the comprehensive inpatient rehabilitation during subacute stroke phase. At 3 months after stroke onset, serum BDNF, proBDNF and MMP-9 will also be measured.
In addition, motor impairment with Fugl-Meyer assessement will be assessed at same time points with serum analysis.
We will compare potential serum biomarkers with motor impairment in stroke patients
- Conventional inpatient rehabilitation Procedure
Intervention Desc: comprehensive inpatient rehabilitation for 2 weeks
Subacute stroke patients who were received the comprehensive inpatients rehabilitation
|Type||Measure||Time Frame||Safety Issue|
|Primary||Serum BDNF||At 2 weeks after the comprehensive inpatient rehabilitation|
|Secondary||Serum proBDNF||At 2 weeks after the comprehensive inpatient rehabilitation|
|Secondary||MMP-9||At 2 weeks after the comprehensive inpatient rehabilitation|
Biospecimen Retention:Samples With DNA - BDNF Val66Met polymorphism